Sahlgrenska Science Park

Anna Törner: Yes, I Am Sick, But Not Weak

”People often say that someone who is ill only has one wish—to get better. But I think that is not true. Someone who is ill also longs to be understood, to be r...

Medicon Village Science Park

Danish biotech to buy struggling American oncology company

Danish drugmaker Pharmacosmos has agreed to acquire American pharmaceutical company G1 Therapeutics in a deal that amounts to 405 million dollars.

The investor: “The major common diseases are hot again”

She has previously been voted Investor of the Year and will now be moderating The Future of Swedish & Danish Life Science congress. We check the temperature of ...

LINK Medical Research

Kompauto Nordic AB

Merck Life Science A/S

Källor: FDA:s vaccinchef tvingas bort – riktar skarp kritik mot Kennedy

Vaccinchefen vid FDA lämnar sin post och kritiserar samtidigt landets hälsominister för att ha låtit ”desinformation och lögner” styra hans tankar om vacciners säkerhet.

Tio life science-projekt får miljonanslag – ny utlysning öppnar

En rad life science-projekt har fått miljonanslag i ett svenskt proof of concept-program. 13 januari öppnar en ny utlysning.

Bio-Works

Thomas Eldered: ”Innovation is the key”

Thomas Eldered speaks in a web clip about the challenges facing the life science sector in the future and what he, as an investor, finds most interesting in new companies.

Optimize Your Visibility

ZEISS presents our newest VersaXRM® 730 3D X-ray microscope.

Italian pharmaceutical company buys rights to immunotherapy from Sanofi

Italy's Recordati buys the rights to a treatment for the rare autoimmune disease cold agglutinin disease (CAD).

A small thing that can solve your problems

If you are in need of a compact valve. Look no further! We have the VOVK

Festo AB

Pharma Relations AB

Are you ready for EMC 2024?

Visit ZEISS at Europe’s largest Event dedicated to Microscopy and Imaging.

Norwegian cancer research companies merge

The Norwegian companies Ultimovacs and Zelluna Immunotherapy plan to merge. At the same time, it is made clear that Ultimovacs' CEO is leaving the company.

Quotient Sciences Limited

Emerson

Galenica AB

Affibody AB

BD separerar affärsområdet Biosciences – fokuserar på medtech

BD slimmar portföljen och avyttrar affärsområdena bioscience och diagnostik. “Nya BD” ska bli ett helgjutet medicinteknikföretag.